Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

M. Robin, LC. de Wreede, C. Wolschke, J. Schetelig, DJ. Eikema, MT. Van Lint, NS. Knelange, D. Beelen, A. Brecht, D. Niederwieser, A. Vitek, W. Bethge, R. Arnold, J. Finke, L. Volin, I. Yakoub-Agha, A. Nagler, X. Poiré, H. Einsele, P. Chevallier,...

. 2019 ; 104 (9) : 1782-1788. [pub] 20190207

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025690

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025690
003      
CZ-PrNML
005      
20201222160333.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.205211 $2 doi
035    __
$a (PubMed)30733269
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Robin, Marie $u Hôpital Saint-Louis, APHP, Université Paris 7, Paris, France marie.robin@aphp.fr.
245    10
$a Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis / $c M. Robin, LC. de Wreede, C. Wolschke, J. Schetelig, DJ. Eikema, MT. Van Lint, NS. Knelange, D. Beelen, A. Brecht, D. Niederwieser, A. Vitek, W. Bethge, R. Arnold, J. Finke, L. Volin, I. Yakoub-Agha, A. Nagler, X. Poiré, H. Einsele, P. Chevallier, E. Holler, P. Ljungman, S. Robinson, A. Radujkovic, D. McLornan, Y. Chalandon, N. Kröger,
520    9_
$a Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a nemoc štěpu proti hostiteli $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a primární myelofibróza $x terapie $7 D055728
650    _2
$a registrace $7 D012042
650    _2
$a indukce remise $7 D012074
650    _2
$a rizikové faktory $7 D012307
650    _2
$a homologní transplantace $7 D014184
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a de Wreede, Liesbeth C $u Department of Biomedical Data Sciences, LUMC, Leiden, the Netherlands and DKMS CTU, Dresden, Germany.
700    1_
$a Wolschke, Christine $u University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Schetelig, Johannes $u Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden, Dresden, Germany.
700    1_
$a Eikema, Diderik-Jan $u EBMT Statistical Unit, Leiden, the Netherlands.
700    1_
$a Van Lint, Maria Teresa $u Ospedale San Martino, Genova, Italy.
700    1_
$a Knelange, Nina Simone $u EBMT Data Office, Leiden, the Netherlands.
700    1_
$a Beelen, Dietrich $u University Hospital, Essen, Germany.
700    1_
$a Brecht, Arne $u Helios HSK Wiesbaden, Wiesbaden, Germany.
700    1_
$a Niederwieser, Dietger $u University Hospital Leipzig, Leipzig, Germany.
700    1_
$a Vitek, Antonin $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Bethge, Wolfgang $u Universität Tübingen, Tübingen, Germany.
700    1_
$a Arnold, Renate $u Charité Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Finke, Jürgen $u Division of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University of Freiburg, Freiburg, Germany.
700    1_
$a Volin, Liisa $u HUCH Comprehensive Cancer Center, Helsinki, Finland.
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, INSERM U995, Lille, France.
700    1_
$a Nagler, Arnon $u Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Poiré, Xavier $u Cliniques Universitaires St. Luc, Brussels, Belgium.
700    1_
$a Einsele, Hermann $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
700    1_
$a Chevallier, Patrice $u CHU Nantes, Nantes, France.
700    1_
$a Holler, Ernst $u University Regensburg, Regensburg, Germany.
700    1_
$a Ljungman, Per $u Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Robinson, Stephen $u Bristol Oncology Centre, Bristol, UK.
700    1_
$a Radujkovic, Alekxandar $u University of Heidelberg, Heidelberg, Germany.
700    1_
$a McLornan, Donal $u Comprehensive Cancer Centre, Department of Haematology, Kings College, London, UK.
700    1_
$a Chalandon, Yves $u Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 9 (2019), s. 1782-1788
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30733269 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160329 $b ABA008
999    __
$a ok $b bmc $g 1599835 $s 1116376
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 9 $d 1782-1788 $e 20190207 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace